Recombinant Human Erythropoietin iorEPOCIM® for the treatment of anemia in pediatric cancer patients

Authors

  • Liliana Martínez Cárdenas Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba
  • Tamara Cedré Hernández Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba
  • Carmen M. López García Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba
  • Mario V. Pichs León Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba
  • Marlene María Ruiz Hernández Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba
  • Marta Beatriz García Caraballoso Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba

Keywords:

erythropoietin, recombinant/therapeutic use, neoplasms, anemia/drug therapy, anemia/radiotherapy, pediatrics

Abstract

Recombinant human erythropoietin is widely used in the treatment of anemia due to cancer. A retrospective, longitudinal and descriptive study was conducted at the Jose Luis Miranda Provincial Pediatric University Hospital in Santa Clara, Villa Clara, to evaluate the impact and effectiveness of the use of the Cuban product iorEPOCIM® in patients who suffer from anemia due to chemotherapy and / or radiotherapyin in the Hematology-Oncology service. An unintentional probabilistic sample was taken by criteria of 38 hospitalized patients who suffered from anemia, in the period from January 2005 to July 2006. The following variables were taken into account: age, sex, race, nutritional status, hemoglobin, transfusions before and after treatment and dose of erythropoietin. It was found that the drug significantly increased hemoglobin levels after four (55.3%, p=0.001) and eight (81.5%, p=0.035) weeks of treatment, with a significant decrease of transfusion requirements (p=0.027 and p=0.032) for both evaluations. The expected impact was not achieved but there was a therapeutic success, which helped to reduce the number of transfusions in patients. Therefore, the use of the medication for the treatment of anemia in these patients is a valuable alternative to improve their quality of life in general and reduces their risk of getting other conditions.

Downloads

Download data is not yet available.

Author Biographies

Liliana Martínez Cárdenas, Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Pediatría. Máster en Atención Integral al Niño. Profesora Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Tamara Cedré Hernández, Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Hematología. Máster en Atención Integral al Niño. Profesora Instructora de la Universidad de Ciencias Médicas “Dr. Serafín Ruiz de Zárate Ruiz” de Villa Clara.

Carmen M. López García, Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Pediatría. Máster en Atención Integral al Niño. Profesora Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Mario V. Pichs León, Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba

Especialista de I y II Grado en Oncología y Radioterapia. Profesor Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Marlene María Ruiz Hernández, Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Pediatría. Máster en Atención Integral al Niño. Profesora Instructora de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Marta Beatriz García Caraballoso, Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Hematología

Downloads

How to Cite

1.
Martínez Cárdenas L, Cedré Hernández T, López García CM, Pichs León MV, Ruiz Hernández MM, García Caraballoso MB. Recombinant Human Erythropoietin iorEPOCIM® for the treatment of anemia in pediatric cancer patients. Acta Méd Centro [Internet]. 2011 Oct. 9 [cited 2025 Aug. 16];5(4):93-104. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/663

Issue

Vol. 5 No. 4 (2011): October-December. Special Issue of Pediatrics

Section

Oncology

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).